Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PSC 04

Drug Profile

PSC 04

Alternative Names: Adipose-derived allogeneic mesenchymal stem cells - Personalized Stem Cells; Allogeneic adipose stem cell therapy - Personalized Stem Cells; COVI-MSC™; PSC-04; STI-8282

Latest Information Update: 02 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Personalized Stem Cells
  • Developer Sorrento Therapeutics
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 17 Apr 2024 Sorrento Therapeutics withdraws phase-IIa trial in Post-acute-COVID-19-syndrome at the unknown location (IV) before enrolment due to bankruptcy (NCT04992247)
  • 09 Jan 2023 Sorrento Therapeutics terminates a Phase-II clinical trial in SARS-COV-2 acute respiratory disease in Brazil (IV), due to slow enrollments (NCT04903327)
  • 18 Jan 2022 Brazilian regulatory agency (ANVISA) authorises phase II trial of PSC 04 in SARS-COV-2 acute respiratory disease
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top